Dr Fonseca Highlights Phase 2 GRIFFIN Study Results for Newly Diagnosed MM

12/13/2021

Rafael Fonseca, MD, Mayo Clinic, discusses new results from the Phase 2 GRIFFIN study of daratumumab, as part of a quadruplet regimen in newly diagnosed multiple myeloma, presented at the 2021 ASH Annual Meeting.

Disclaimer: The views and opinions expressed are those of the author(s) and do not necessarily reflect the official policy or position of Oncology Learning Network or HMP Global, their employees, and affiliates. Any content provided by our bloggers or authors are of their opinion and are not intended to malign any religion, ethnic group, club, association, organization, company, individual, anyone, or anything.

Recent News

News

Post-Transplantation Cyclophosphamide vs ATG for GVHD Prophylaxis Among Patients Undergoing Allogeneic Stem Cell Transplant From Mismatched Unrelated Donors

07/02/2024

Amber Denham ;

A retrospective analysis demonstrated that post-transplantation cyclophosphamide yielded survival and non-relapse mortality benefit compared to anti-thymocyte globulin treatment for GVHD prophylaxis among patients undergoing allogeneic stem...

A retrospective analysis...

07/02/2024

Oncology

News

Study Findings Show Considerable Disease Burden of NF1-PN Among Affected Patients

07/01/2024

Janelle Bradley ;

Findings from the real-world CASSIOPEA study show the considerable disease burden of neurofibromatosis type 1 with plexiform neurofibromas (NF1-PN) highlighting the importance of effective treatments for this patient population.

Findings from the real-world...

07/01/2024

Oncology

News

Vinblastine/Methotrexate Fails to Demonstrate Activity for NF1-PN in Pediatric and Young-Adult Patients

07/01/2024

Janelle Bradley ;

Findings from a phase 2 study show vinblastine/methotrexate did not demonstrate activity for neurofibromatosis type 1 with plexiform neurofibromas (NF1-PN) in pediatric and young-adult patients, despite being well-tolerated.

Findings from a phase 2 study...

07/01/2024

Oncology

News

07/01/2024

Janelle Bradley ;

Study findings show neurofibromatosis type 1 with plexiform neurofibromas (NF1-PN) worsens adult patient and caregiver health-related quality of life vs that of the general population.

Study findings show...

07/01/2024

Oncology

FDA Approval

FDA Approves New Formulation of Thiotepa for Patients With Breast and Ovarian Cancer

07/01/2024

Stephanie Holland ;

The FDA has approved the new drug application for SH-105, a liquid formulation of thiotepa, for the treatment of patients with breast and ovarian cancer.

The FDA has approved the new...

07/01/2024

Oncology

FDA Approval

FDA Approves Epcoritamab for Relapsed/Refractory Follicular Lymphoma

06/26/2024

The FDA granted accelerated approval to epcoritamab-bysp for the treatment of adult patients with relapsed or refractory follicular lymphoma who received ≥2 prior lines of therapy.

The FDA granted accelerated...

06/26/2024

Oncology

Conference Coverage

Erdafitinib Shows Promising Clinical Efficacy, Safety Among Pre-Treated Patients With FGFR-Altered Non-Small Cell Lung Cancer

06/26/2024

Stephanie Holland ;

According to results from the phase 2 RAGNAR study, erdafitinib demonstrated promising clinical activity among pre-treated patients with non-small cell lung cancer (NSCLC) harboring pre-specified FGFR alterations.

According to results from the...

06/26/2024

Oncology

News

Iomab-B Led Allogeneic Hematopoietic Cell Transplantation vs Standard of Care for Older Patients With R/R AML

06/25/2024

According to data from the 2024 EHA Congress, long-term results of the phase 3 SIERRA trial demonstrated that conditioning and induction with 131I-apamistamab (Iomab-B) was well-tolerated and allowed for access to HCT with curative potential...

According to data from the 2024...

06/25/2024

Oncology

News

Olutasidenib Demonstrates Efficacy for Patients With R/R IDH1-Mutated AML Previously Treated With Venetoclax

06/24/2024

Olutasidenib treatment demonstrated efficacy and a consistent safety profile for patients with relapsed/refractory mutant IDH1 acute myeloid leukemia previously treated with venetoclax, according to a subset analysis from a phase 2 study.

Olutasidenib treatment...

06/24/2024

Oncology

News

FDA Grants Accelerated Approval to Adagrasib With Cetuximab for Patients With KRAS G12C-Mutated Colorectal Cancer

06/21/2024

Based on results from the KRYSTAL-1 trial, the FDA has granted accelerated approval to adagrasib with cetuximab for patients with KRAS G12C-mutated colorectal cancer.

Based on results from the...

06/21/2024

Oncology